secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001725160-23-000053
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis subleases NYC office to LM Cohen for $1.5M/yr; term through 2032
-------------------------------------------------------------------------

- Sublease covers suites 1710 and 1800 at 1359 Broadway, New York, with LM Cohen & Co. LLP as subtenant.
- Term starts May 1, 2023 (or later if landlord consent delayed) and ends November 29, 2032.
- Base rent ~$1.5M/yr ($128k/mo) first 5 years, then ~$1.7M/yr ($141k/mo); 14-month rent abatement included.
- Zentalis remains primarily liable under original lease with Landlord ESRT 1359 Broadway; sublease terminates if original lease ends.
- Agreement reduces Zentalis's direct occupancy cost but still requires landlord consent per Lease terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000053/0001725160-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000053/zntl-20230306.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer